Christopher M Bartley
Christopher M Bartley
1Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States
2Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, United States
1,2,†,
Neelroop N Parikshak
Neelroop N Parikshak
1Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States
3Department of Neurology, University of California, San Francisco, San Francisco, CA, United States
1,3,†,
Thomas T Ngo
Thomas T Ngo
1Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States
2Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, United States
1,2,
Jessa A Alexander
Jessa A Alexander
1Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States
3Department of Neurology, University of California, San Francisco, San Francisco, CA, United States
1,3,
Kelsey C Zorn
Kelsey C Zorn
4Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, United States
4,
Bonny D Alvarenga
Bonny D Alvarenga
1Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States
3Department of Neurology, University of California, San Francisco, San Francisco, CA, United States
1,3,
Min K Kang
Min K Kang
1Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States
3Department of Neurology, University of California, San Francisco, San Francisco, CA, United States
1,3,
Massimo Pedriali
Massimo Pedriali
5Operative Unit of Surgical Pathology, Azienda Ospedaliera-Universitaria, Ferrara, Italy
5,
Samuel J Pleasure
Samuel J Pleasure
1Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States
3Department of Neurology, University of California, San Francisco, San Francisco, CA, United States
1,3,
Michael R Wilson
Michael R Wilson
1Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States
3Department of Neurology, University of California, San Francisco, San Francisco, CA, United States
1,3,*
1Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States
2Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, United States
3Department of Neurology, University of California, San Francisco, San Francisco, CA, United States
4Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, United States
5Operative Unit of Surgical Pathology, Azienda Ospedaliera-Universitaria, Ferrara, Italy
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
✉*Correspondence: Michael R. Wilson michael.wilson@ucsf.edu
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology
†These authors have contributed equally to this work
Received 2022 Mar 2; Accepted 2022 Mar 4; Collection date 2022.
Keywords: paraneoplastic neurologic disease, myelopathy, anti-Yo antibodies, phage display, breast cancer, CDR2L
Copyright © 2022 Bartley, Parikshak, Ngo, Alexander, Zorn, Alvarenga, Kang, Pedriali, Pleasure and Wilson.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
